Morbid Obesity Due to Prolactinoma and Significant Weight Loss After Dopamine Agonist Treatment

Morbid Obesity Due to Prolactinoma and Significant Weight Loss After Dopamine Agonist Treatment

Objective: Morbid obesity may be related to a prolactinoma, although uncommon, and can lead to adverse effects like insulin resistance and metabolic syndrome. Recent research suggests that hyperprolactinemia causes an abnormal lipid profile, weight gain, and cardiovascular diseases. Moreover, high p...

Full description

Bibliographic Details
Main Authors: Muzaffar Ali, MBBS, Lubna Mirza, MD
Format: Article
Language:English
Published: Elsevier 2021-05-01
Series:AACE Clinical Case Reports
Subjects:
dopamine agonist
endocrinology
morbid obesity
prolactinoma
weight loss
Online Access:http://www.sciencedirect.com/science/article/pii/S2376060521000134

Internet

http://www.sciencedirect.com/science/article/pii/S2376060521000134

Similar Items